Structure, signaling and the drug discovery of the Ras oncogene protein

키워드

참고문헌 (57)

1. Cox AD, "Ras history: The saga continues", Small GTPases, 1, pp.2~27 (2010)
2. Victor T, "No evidence for point mutations in codons 12, 13, and 61 of the ras gene in a high-incidence area for esophageal and gastric cancers", Cancer Res, 50, pp.4911~4914 (1990)
3. Chang YS, "Detection of N-, H-, and KRAS codons 12, 13, and 61 mutations with universal RAS primer multiplex PCR and N-, H-, and KRAS-specific primer extension", Clin Biochem, 43, pp.296~301 (2010)
4. Berns A, "Kras and Hras—what is the difference?", Nat Genet, 40, pp.1149~1150 (2008)
5. Eungdamrong NJ, "Computational approaches for modeling regulatory cellular networks", Trends Cell Biol, 14, pp.661~669 (2004)
6. Brock EJ, "How to target activated Ras proteins: direct inhibition vs. induced mislocalization", Mini Rev Med Chem, 16, pp.358~369 (2016)
7. Milburn MV, "Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins", Science, 247, pp.939~945 (1990)
8. De Luca A, "The RAS", RAF, ERK and the PI3K, pp.AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches, Expert Opin Ther Targets[DOI]
9. Bos JL, "Ras-like GTPases", Biochim Biophys Acta, 1333, pp.19~31 (1997)
10. Touchot N, "Four additional members of the ras gene superfamily isolated by an oligonucleotide strategy: molecular cloning of YPT-related cDNAs from a rat brain library", Proc Natl Acad Sci U S A, 84, pp.8210~8214 (1987)
11. Wittinghofer A, "Structure-function relationships of the G domain, a canonical switch motif", Annu Rev Biochem, 80, pp.943~971 (2011)
12. Ostrem JM, "K-Ras (G12C) inhibitors allosterically control GTP affinity and effector interactions", Nature, 503, pp.548~551 (2013)
13. Prior IA, "A comprehensive survey of Ras mutations in cancer", Cancer Res, 72, pp.2457~2467 (2012)
14. Reiss Y, "Inhibition of purified p21ras farnesyl: protein transferase by Cys-AAX tetrapeptides", Cell, 62, pp.81~88 (1990)
15. Michaelson D, "Postprenylation CAAX processing is required for proper localization of Ras but not Rho GTPases", Mol Biol Cell, 16, pp.1606~1616 (2005)
16. Manolaridis I, "Mechanism of farnesylated CAAX protein processing by the intramembrane protease Rce1", Nature, 504, pp.301~305 (2013)
17. Hancock JF, "Ras plasma membrane signalling platforms", Biochem J, 389, pp.1~11 (2005)
18. Smith MJ, "Integrated RAS signaling defined by parallel NMR detection of effectors and regulators", Nat Chem Biol, 10, pp.223~230 (2014)
19. Scheffzek K, "The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants", Science, 277, pp.333~339 (1997)
20. Feig LA, "Tools of the trade: use of dominantinhibitory mutants of Ras-family GTPases", Nat Cell Biol, 1, pp.25~27 (1999)
21. Roberts PJ, "Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer", Oncogene, 26, pp.3291~3310 (2007)
22. Leicht DT, "Raf kinases: function, regulation and role in human cancer", Biochim Biophys Acta, 1773, pp.1196~1212 (2007)
23. Downward J, "Targeting RAS signalling pathways in cancer therapy", Nat Rev Cancer, 3, pp.11~22 (2003)
24. Manna PR, "The role of specific mitogen-activated protein kinase signaling cascades in the regulation of steroidogenesis", J Signal Transduct, 2011, pp.821615~ (2011)
25. Zhang W, "MAPK signal pathways in the regulation of cell proliferation in mammalian cells", Cell Res, 12, pp.9~18 (2002)
26. Wong KK, "Targeting the PI3K signaling pathway in cancer", Curr Opin Genet Dev, 20, pp.87~90 (2010)
27. Eser S, "Selective requirement of PI3K", PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer, 2013, pp.23, 406~420
28. Pearce LR, "The nuts and bolts of AGC protein kinases", Nat Rev Mol Cell Biol, 11, pp.9~22 (2010)
29. Sadeghi N, "Targeting the PI3K pathway for cancer therapy", Future Med Chem, 4, pp.1153~1169 (2012)
30. Welch HC, "Phosphoinositide 3‐kinase‐dependent activation of Rac", FEBS Lett, 546, pp.93~97 (2003)
31. Hao Y, "RalGDS couples growth factor signaling to Akt activation", Mol Cell Biol, 28, pp.2851~2859 (2008)
32. Kashatus DF, "Ral GTPases in tumorigenesis: emerging from the shadows", Exp Cell Res, 319, pp.2337~2342 (2013)
33. Bunney TD, "Phospholipase C epsilon: linking second messengers and small GTPases", Trends Cell Biol, 16, pp.640~648 (2006)
34. Urtreger AJ, "Contribution of individual PKC isoforms to breast cancer progression", IUBMB Life, 64, pp.18~26 (2012)
35. Leshchiner ES, "Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices", Proc Natl Acad Sci U S A, 112, pp.1761~1766 (2015)
36. Aviel-Ronen S, "K-ras mutations in non-small-cell lung carcinoma: a review", Clin Lung Cancer, 8, pp.30~38 (2006)
37. Chang YS, "Detection of N-, H-, and KRAS codons 12, 13, and 61 mutations with universal RAS primer multiplex PCR and N-, H-, and KRAS-specific primer extension", Clin Biochem, 43, pp.296~301 (2010)
38. Repasky GA, "Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?", Trends Cell Biol, 14, pp.639~647 (2004)
39. Westcott PM, "The genetics and biology of KRAS in lung cancer", Chin J Cancer, 32, pp.63~70 (2013)
40. Cox AD, "Drugging the undruggable RAS: mission possible?", Nat Rev Drug Discov, 13, pp.828~851 (2014)
41. Papke B, "Drugging RAS: Know the enemy", Science, 355, pp.1158~1163 (2017)
42. Hunter JC, "In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C", Proc Natl Acad Sci U S A, 111, pp.8895~8900 (2014)
43. Boch C, "The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study", BMJ Open, 3, pp.e002560~ (2013)
44. Lim SM, "Therapeutic Targeting of Oncogenic K‐Ras by a Covalent Catalytic Site Inhibitor", Angew Chem Int Ed Engl, 53, pp.199~204 (2014)
45. Bos JL, "GEFs and GAPs: critical elements in the control of small G proteins", Cell, 129, pp.865~877 (2007)
46. Winter JJ, "Small molecule binding sites on the Ras: SOS complex can be exploited for inhibition of Ras activation", J Med Chem, 58, pp.2265~2274 (2015)
47. Maurer T, "Smallmolecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity", Proc Natl Acad Sci U S A, 109, pp.5299~5304 (2012)
48. Patgiri A, "An orthosteric inhibitor of the Ras-Sos interaction", Nat Chem Biol, 7, pp.585~587 (2011)
49. Capell BC, "Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome", Proc Natl Acad Sci U S A, 102, pp.12879~12884 (2005)
50. Baker NM, "Cancer: Drug for an 'undruggable' protein", Nature, 497, pp.577~578 (2013)
51. Steelman LS, "Roles of the Raf", MEK, PTEN, pp.Akt, mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging[DOI]
52. Cervello M, "Molecular mechanisms of sorafenib action in liver cancer cells", Cell Cycle, 11, pp.2843~2855 (2012)
53. Samant RS, "Recent advances in anti-angiogenic therapy of cancer", Oncotarget, 2, pp.122~134 (2011)
54. Aronov AM, "Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control", J Med Chem, 52, pp.6362~6368 (2009)
55. Do K, "Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer", Invest New Drugs, 33, pp.720~728 (2015)
56. Najumudeen AK, "Cancer stem cell drugs target K-ras signaling in a stemness context", Oncogene, 35, pp.5248~5262 (2016)
57. Ledford H, "Cancer: The ras renaissance", Nature, 520, pp.278~280 (2015)

관련 논문AI추천